No improvement in freedom from progression rates for patients: Study

Results from the NRG Oncology NRG-RTOG 0232 clinical trial adding external beam radiotherapy (EBRT) to brachytherapy (BT) in men with intermediate-risk prostate cancer indicate that there was no improvement in freedom from progression (FFP) rates for patients.

Related Keywords

Phoenix ,Arizona ,United States ,Jeff Michalski ,Danielle Ellis ,Washington University Siteman Cancer Center ,National Cancer Institute ,Clinical Oncology ,Study Lead Author ,Washington University Siteman Cancer ,Brachytherapy ,Dancer ,Prostate ,Prostate Cancer ,Clinical Trial ,Xternal Beam Radiotherapy ,Ncology ,Radiation Therapy ,Radiotherapy ,Research ,